Hidden liver scarring is common and often symptomless. Large population analyses using vibration-controlled transient elastography in the United States found that controlled attenuation parameter and liver stiffness measurements detect far more steatosis and fibrosis than routine liver blood tests: Xiaotao Zhang of Baylor College of Medicine and Natalia I. Heredia of The University of Texas Health Science Center at Houston reported elevated NAFLD prevalence and a substantial proportion with significant fibrosis in NHANES 2017–2018 data. Community screening led by Wayne Eskridge of the Fatty Liver Foundation and John M. Vierling of Baylor College of Medicine identified many asymptomatic adults with steatosis or steatosis-plus-fibrosis who otherwise would be missed.
How liver scarring goes unnoticed Liver fibrosis progresses silently because early damage rarely causes pain or specific complaints, and serum aminotransferase concentrations are insensitive: normal or mildly elevated enzymes frequently occur in patients with advanced disease. Transient elastography (FibroScan) combined with CAP gives a rapid, noninvasive estimate of both steatosis and stiffness and has been validated against imaging and biopsy in multiple cohorts, making it useful for case-finding beyond standard blood tests. These technical and clinical observations are summarized in the AASLD practice guidance authored by Naga Chalasani and colleagues at Indiana University School of Medicine and in methodological reviews of VCTE performance.
What doctors now recommend European practice panels chaired by Frank Tacke of Charité – Universitätsmedizin Berlin support a stepwise case-finding strategy: use simple blood-based risk scores such as FIB-4 in primary care for adults with cardiometabolic risk factors, and follow elevated scores with transient elastography to identify advanced fibrosis for specialist referral. The American Association for the Study of Liver Diseases practice guidance led by Naga Chalasani does not endorse universal population screening but recognizes targeted assessment for patients with risk factors; community and primary-care case-finding programs have proven feasible and effective in identifying at-risk middle-aged adults.
Relevance, causes and consequences Obesity, type 2 diabetes, hypertension and dyslipidemia drive steatosis and fibrosis progression; genetic variants like PNPLA3 increase risk in Hispanic and some Asian populations, which helps explain higher regional burdens reported in North and South America. Untreated progressive disease can lead to cirrhosis, portal hypertension, liver failure and hepatocellular carcinoma; early detection creates a window for evidence-based action: structured weight loss, dietary changes, physical activity and metabolic control reduce progression risk, and patients with F2–F3 fibrosis benefit from hepatology assessment and consideration for clinical trials or specialist therapies. These recommendations are grounded in population data and international guidelines and should be adapted to local healthcare capacity, cultural dietary patterns and resource availability.